Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY21 results · Apr–Jun 2020
Sun Pharma Advanced Research Company reported revenue from operations of ₹185.45 crore (up 970.7% from Q1 FY20) and net profit of ₹56.69 crore for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 185.45 | 17.32 | +970.7% | 22.71 | +716.6% |
| Other income | 0.66 | 3.67 | −82.0% | 3.12 | −78.8% |
| Total income | 186.11 | 20.99 | +786.7% | 25.83 | +620.5% |
| Profit before tax | 56.69 | (94.19) | Turned profit | (99.54) | Turned profit |
| Net profit for the period | 56.69 | (94.19) | Turned profit | (99.54) | Turned profit |
| EPS, basic (₹) | 2.16 | (3.59) | Turned profit | (3.80) | Turned profit |
| Net margin (%) | 30.6 | -543.8 | -438.3 |
Standalone
- Filed with BSE
- 05 Aug 2020, 17:57 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE